Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Preferred Shares (2017 - 2025)

PAVmed has reported Preferred Shares over the past 6 years, most recently at $3.7 million for Q4 2025.

  • For Q4 2025, Preferred Shares changed N/A year-over-year to $3.7 million; the TTM value through Dec 2025 reached $3.7 million, changed N/A, while the annual FY2025 figure was $3.7 million, N/A changed from the prior year.
  • Preferred Shares for Q4 2025 was $3.7 million at PAVmed, up from $3.6 million in the prior quarter.
  • Over five years, Preferred Shares peaked at $3.7 million in Q4 2025 and troughed at $2.4 million in Q3 2021.
  • A 5-year average of $2.9 million and a median of $2.8 million in 2023 define the central range for Preferred Shares.
  • Biggest five-year swings in Preferred Shares: decreased 4.65% in 2021 and later increased 11.56% in 2022.
  • Year by year, Preferred Shares stood at $2.4 million in 2021, then rose by 11.41% to $2.7 million in 2022, then grew by 11.06% to $3.0 million in 2023, then grew by 5.28% to $3.2 million in 2024, then rose by 16.31% to $3.7 million in 2025.
  • Business Quant data shows Preferred Shares for PAVM at $3.7 million in Q4 2025, $3.6 million in Q3 2025, and $3.5 million in Q2 2025.